HTA Methodology Shifts & Alzheimer's Access

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, particularly the Alzheimer's access landscape shifting again.

MarcusSame here. We're looking at FDA's new RWE guidance for accelerated approvals — what this means for evidence generation in neurodegenerative diseases. Then NICE's threshold consultation implications for highly specialized technologies. And CMS Part D redesign operational hurdles as implementation approaches.

SaraThat second one is interesting to me — the threshold consultation comes at a time when payers are increasingly being asked to absorb ultra-orphan therapies with uncertain long-term outcomes. The budget impact question there is one the field hasn't fully worked out yet.

MarcusExactly. Let's get into it.

MarcusStarting with the FDA's draft guidance on real-world evidence for accelerated approvals in neurodegenerative diseases. This is significant because it formalizes pathways for using RWE to support approvals when traditional endpoints are challenging. What strikes me here is the explicit recognition that diseases like Alzheimer's and Parkinson's require novel evidence approaches.

SaraThat's one read — I'd frame it slightly differently though. The guidance is welcome, but the part that gives me pause is how it balances scientific rigor with practical feasibility. Payers will be looking at how this RWE translates into meaningful real-world outcomes that justify the price tags these therapies carry.

MarcusThat's fair, though I think payers would see this as actually creating more certainty rather than less. By establishing clear parameters for RWE use, FDA is essentially saying 'here's what constitutes acceptable evidence.' What's striking to me is the emphasis on prospective data collection rather than retrospective analysis.

SaraRight, and from the payer side, prospective data collection is exactly what we need to see more of. But I keep coming back to the implementation challenges. How will this guidance interact with existing HTA frameworks that often prioritize randomized controlled trial data? The harmonization question between regulatory and reimbursement evidence requirements remains.

MarcusThat connects to something I keep coming back to — the FDA isn't setting HTA policy here, they're creating regulatory pathways. The real question is how manufacturers will leverage this guidance to build more compelling value propositions that speak to both regulators and payers. The Alzheimer's space is particularly interesting given the recent controversies around surrogate endpoints.

SaraAlzheimer's is indeed the elephant in the room here. What we're seeing is a fundamental tension between the need for innovation and the imperative for robust evidence. The guidance acknowledges this tension but doesn't fully resolve it. I wonder if that's the full picture though — this guidance might actually create more questions than answers about how these therapies will be valued in practice.

MarcusI'd push back slightly on that. This guidance provides clarity that's been missing. The fact that it specifically addresses neurodegenerative diseases shows FDA is adapting to therapeutic areas where traditional endpoints don't capture meaningful clinical benefit. What's genuinely interesting is how this might accelerate the development of composite endpoints that combine RWE with traditional measures.

SaraThe composite endpoint point is well taken. But what strikes me is the operational burden this places on manufacturers. Developing robust RWE infrastructure requires significant investment, and we know that smaller companies in rare disease spaces may struggle to meet these new expectations. The equity implications here are worth considering.

MarcusThat's a fair point about resource allocation. But I'd argue that this guidance actually levels the playing field by establishing clear expectations. Companies that invest in RWE capabilities will be better positioned regardless of size. The alternative — continuing with ambiguous requirements — creates more uncertainty for everyone.

SaraI suppose that's true. Though I remain skeptical about how this will translate into actual access. The guidance doesn't address the fundamental question of how payers will evaluate these novel evidence streams. That's the piece that still feels unresolved to me.

MarcusLet's move to NICE's threshold consultation for highly specialized technologies. This is happening against a backdrop of increasing ultra-orphan approvals and rising cost pressures in the UK system. What caught me off guard is the explicit consideration of £50,000-£100,000 per QALY thresholds for certain technologies.

SaraThis is one of those stories where the procedural timeline matters almost as much as the substance. The consultation is happening now, but the actual implementation won't be until next year. That gives stakeholders time to respond, but also means we're looking at a period of uncertainty for manufacturers planning their UK market access strategies.

MarcusExactly, and what's significant is how this consultation explicitly acknowledges the financial reality of ultra-orphan therapies. The fact that they're considering thresholds above the traditional £20,000-£30,000 range shows recognition that these therapies often serve small populations with high unmet need.

SaraThat's fair, though I think payers would see this as more of a political compromise than a principled approach. The budget impact question remains unresolved. How do you justify spending £100,000 per QALY on one ultra-orphan when that same money could fund multiple treatments for more common conditions? That's the tension that keeps me up at night.

MarcusI wonder if that's the full picture though. This consultation might actually be creating more flexibility for NICE to recommend technologies that provide significant benefit even if they don't meet traditional cost-effectiveness thresholds. The patient voice in this conversation has been particularly strong, which is a positive development.

SaraThe patient voice is indeed prominent, but I remain concerned about the precedent this sets. If we start accepting higher thresholds for ultra-orphan therapies, where does that end? The slippery slope argument isn't just theoretical — it's a real budgetary concern for healthcare systems already under significant strain.

MarcusThat connects to something I keep coming back to — the fundamental question of how we value innovation. This consultation is essentially asking 'what are we willing to pay for transformative therapies?' It's not just about cost-effectiveness anymore; it's about system priorities and value judgments that go beyond pure economics.

SaraSystem priorities are exactly what's at stake here. And from a payer perspective, the consultation doesn't adequately address how these higher thresholds will interact with existing budget impact assessments. The practical implications for formulary decisions remain unclear, which creates uncertainty for all stakeholders.

MarcusLet's turn to CMS Part D redesign implementation challenges. This is now becoming real as we approach the operational phase. What's striking to me is how the implementation is exposing gaps in the original design, particularly around the coverage gap modifications for biologics.

SaraImplementation challenges are inevitable with something this complex, but what caught my attention was the recent CMS announcement about operational hurdles related to prior authorization requirements. The system wasn't designed to handle the volume of exceptions requests that are coming in, creating administrative burdens that could undermine the intended cost savings.

MarcusThat's one read — I'd frame it slightly differently though. The implementation challenges are actually highlighting areas where the redesign is working as intended. The fact that beneficiaries are accessing more medications in the coverage gap is a positive outcome. The administrative burden is a short-term issue that will be resolved as systems adapt.

SaraThe short-term/long-term distinction is important, but I'm concerned about the immediate impact on patient access. The prior authorization requirements are creating delays that could have real clinical consequences. What strikes me is how these implementation issues disproportionately affect vulnerable populations who may not have the resources to navigate complex systems.

MarcusRight, and from the payer side, there's a tension between controlling costs and ensuring timely access. The Part D redesign was always going to be a balancing act, but what's genuinely interesting is how it's accelerating the adoption of value-based purchasing models in Medicare Advantage plans.

SaraValue-based purchasing is indeed emerging as a key theme, but I remain skeptical about how these models will be evaluated without robust outcome measures. The CMS hasn't yet articulated clear metrics for success, which creates uncertainty about whether the redesign is achieving its intended goals of improving value while maintaining access.

MarcusThat's fair, though I think CMS would argue that the value-based models are still in the early stages of development. The fact that they're experimenting with different approaches is actually a strength, allowing for course correction as more data becomes available.

SaraExperimentation is good, but without clear evaluation frameworks, we're essentially flying blind. The budget impact question remains unanswered — how will we know if these changes are actually improving value for money? That's the piece that still feels unresolved to me.

MarcusLet's discuss the EMA's expansion of the rare disease adaptive pathway. This is significant because it's creating a more streamlined approach for developing therapies in areas with high unmet need. What I find particularly interesting is how this pathway explicitly addresses the evidence requirements for ultra-rare conditions.

SaraThis is one of those stories where the procedural timeline matters almost as much as the substance. The expansion is happening now, but the full operational framework won't be in place until later this year. That gives stakeholders time to prepare, but also means we're looking at a period of uncertainty for manufacturers planning their development strategies.

MarcusExactly, and what's significant is how this pathway acknowledges the unique challenges of developing therapies for ultra-rare conditions. The emphasis on flexible study designs and reduced evidentiary requirements shows EMA adapting to the realities of rare disease development.

SaraThe flexibility is welcome, but I remain concerned about the methodological rigor. What strikes me is how this pathway might create divergent evidence standards between rare and common diseases. The budget impact question remains unresolved — how will HTA bodies evaluate therapies developed through these more flexible pathways?

MarcusI wonder if that's the full picture though. This pathway isn't about lowering standards; it's about developing appropriate standards for specific therapeutic contexts. The fact that it maintains scientific rigor while acknowledging operational realities is actually a strength.

SaraMaintaining scientific rigor is easier said than done. The pathway's emphasis on post-authorization studies creates its own set of challenges. How will these studies be designed to generate meaningful real-world evidence? And who will bear the cost of these studies? Those are the questions that keep me up at night.

MarcusThat connects to something I keep coming back to — the fundamental question of how we balance innovation with evidence generation. This pathway is essentially creating a more pragmatic approach to rare disease development that recognizes the limitations of traditional clinical trial methods in ultra-rare populations.

SaraThe pragmatic approach is necessary, but I remain concerned about the precedent this sets. If we accept more flexible evidence requirements for rare diseases, where does that end? The slippery slope argument isn't just theoretical — it's a real methodological concern for healthcare systems evaluating these therapies.

MarcusI'd push back slightly on that. This pathway is actually creating more transparency about the evidence requirements, which is a positive development. The fact that it explicitly addresses the unique challenges of rare disease development shows regulators adapting to therapeutic realities.

SaraTransparency is good, but without clear evaluation criteria, we're essentially operating in a gray area. The budget impact question remains unanswered — how will payers assess the value of therapies developed through these more flexible pathways? That's the piece that still feels unresolved to me.

SaraA lot to think about today. I'll be watching how the NICE threshold consultation evolves and whether it leads to more formalized approaches for ultra-orphan therapies.

MarcusSame — and for me the thread running through today is the tension between innovation and evidence generation across different regulatory and reimbursement systems. Each system is finding its own balance, but the lack of harmonization creates complexity for manufacturers.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.